coidosis recommendations propose 2 diagnostic pathways: histological and clinical. 6 The histological pathway requires a positive endomyocardial biopsy (EMB). However, EMB is limited in its sensitivity because of the patchy and dynamic nature of the disease. 7, 8 Therefore, a clinical pathway may be pursued for diagnosis. This requires histological evidence of extracardiac sarcoidosis coupled with clinical evidence of cardiac pathology that is consistent with CS. Vita and colleagues 9 recently studied 107 patients with known or suspected CS who were referred for cardiac MRI (CMR) and cardiac positron emission tomography (PET); 38 of these patients underwent EMB, of whom 3 were positive for CS. At the same time, 21 of the 38 patients had imaging findings consistent with a diagnosis of CS. This finding supports the concept that the clinical pathway, especially when CMR and PET are used in a complementary fashion, may be more sensitive than the histological pathway for diagnosing CS. Furthermore, there is accumulating evidence for the existence of sarcoidosis that is limited to the heart or isolated cardiac sarcoidosis (ICS). 4 This entity cannot be diagnosed via the current clinical pathway. 4 The prevalence of ICS has not been well established, with estimates varying from 3% to 29% of patients with CS. 4, 10 The reasons for this wide range of estimates may reflect both variability in the sample populations and the lack of an agreed-on definition. However, when a strict definition is used (absence of extracardiac disease on whole-body imaging, skin examination, and eye examination), ICS appears to be rare, with a prevalence of ≈3%. 10 Additionally a variety of other clinical entities, including arrhythmogenic right ventricular cardiomyopathy, 11 right ventricular (RV) cardiomyopathy of unspecified significance, 12 and unexplained cardiomyopathy with evidence of occult inflammation, 13 may mimic, represent early phases of, or overlap with CS. Dechering and colleagues 11 compared 8 patients with CS and 10 patients with arrhythmogenic right ventricular cardiomyopathy. They showed that 5 of the 8 patients with established CS also fulfilled diagnostic criteria for arrhythmogenic right ventricular cardiomyopathy.
Therefore, there is a need for more sensitive and specific diagnostic criteria for CS. To increase diagnostic sensitivity, future guidelines could deemphasize the role of biopsy. In the study mentioned earlier by Vita and colleagues, 9 the complementary use of PET and CMR enabled accurate reclassification of the likelihood of CS in 45% of cases. Because the complementary use of CMR and PET may enable an imaging-based diagnosis of CS, future guidelines may consider permitting a second clinical pathway for the diagnosis of CS: a diagnosis of probable CS may be made, without the need for either EMB or extracardiac biopsy, if there are both: (1) an uptake pattern of 18-flourodeoxyglucose (FDG) on cardiac PET consistent with CS, and (2) a late gadolinium enhancement (LGE) pattern on CMR consistent with CS. This would also enable a clinical pathway for the diagnosis of ICS. The Japanese Circulation Society recently updated their Guidelines for Diagnosis and Treatment of Cardiac Sarcoidosis in a similar fashion so as to permit a clinical diagnosis of ICS.
14 Developing technologies may eventually provide further diagnostic alternatives to biopsy. For example, nuclear magnetic resonance spectroscopy of the salivary metabolome has shown promise in distinguishing patients with and without systemic sarcoidosis. 15 Furthermore, the use of voltage guidance has shown promise in improving the diagnostic yield of EMB in patients with CS.
16 Table 1 summarizes the 2014 HRS Expert Consensus Recommendations on Criteria for Diagnosis of CS 6 and provides suggested updates to these recom- mendations based on data that have become available since its publication.
ARRHYTHMOGENIC SUBSTRATE
Scar secondary to inflammatory damage from sarcoid granulomas is thought to be the dominant substrate for ventricular tachycardia (VT) in patients with CS. 17, 18 The pattern and location of involvement vary widely. Any segment of the left or right ventricle and any layer of the myocardium may be affected. 9, [17] [18] [19] [20] [21] [22] Within the left ventricle, scar tends to be patchy, and the septum is the most common site of involvement, followed by the anterior wall, the left ventricular outflow tract, the inferior wall, the lateral wall, and the apex. 17 The most common depths of involvement are midmyocardial and subepicardial. 9, 17 Isolated subepicardial involvement is more common in patients with preserved left ventricular systolic function. 17 Subepicardial scar tends to focus at the basal septum, lateral mitral annulus, posterobasal septum, and left ventricular summit, and it does not necessarily overlie areas of endocardial involvement. 17 Within the RV, scar tends to be confluent, and all segments appear to be affected with equal frequency. 17 Subepicardial scar in the RV tends to overlie areas of subendocardial involvement. 17 Isolated RV involvement is rare, suggesting that RV involvement generally follows left ventricular involvement and may represent a more advanced stage of disease. 23 The Figure shows representative imaging and electrophysiology findings in patients with CS.
The role of inflammation in ventricular arrhythmogenesis in patients with CS is not well established. Although inflammation may lead to scar, which in turn may serve as an arrhythmogenic substrate, studies conflict with respect to whether disease activity is arrhythmogenic. 5, 24, 25 Banba and colleagues 25 studied 14 patients with CS and new onset arrhythmias. Among these patients, 7 had sustained VT, only 1 of whom had cardiac inflammation by Gallium-67 citrate scintigraphy. This finding suggests that downstream fibrosis rather than disease activity is the primary driver of VA in patients with CS.
Blankstein and colleagues 24 studied 118 patients with suspected CS, in whom the presence of focal FDG uptake on cardiac PET, indicating inflammation, predicted future VT or death. Although this finding suggests that disease activity may play a significant role in arrhythmogenesis in CS, the retrospective nature of the study leaves open the possibility that downstream fibrosis was the primary driver of arrhythmia.
Last, Muser and colleagues 26 studied 29 patients with CS and VT undergoing CMR, PET, and electroana- tomical mapping. Myocardial segments with abnormal electrograms tended to have more scar by CMR and less inflammation by PET. These results provide evidence that scar, not inflammation, plays the dominant role in ventricular arrhythmogenesis in CS.
In addition to ventricular scar and inflammation, the His-Purkinje system may participate in VA in patients with CS. Naruse and colleagues 18 studied 14 patients with CS and sustained VT undergoing electrophysiology study. Among 37 inducible VTs, they identified 2 distinct electrophysiological phenotypes: scar-related VT (31 VTs) and Purkinje-related VT (6 VTs). Purkinje involvement was established when Purkinje potentials were observed in sinus rhythm and always preceded the VT-QRS onset by ≥20 ms. Purkinje-related VTs were equally likely to originate from the left anterior fascicle (2 VTs), left posterior fascicle (2 VTs), and right bundle branch (2 VTs) and were less likely to be reentrant (4 of 6 versus 31 of 31 scar-related VTs).
RISK STRATIFICATION
VAs may be the presenting symptom of CS 20, 27 and are a significant predictor of mortality in patients with CS. 28 The incidence of VA in patients with CS is not well defined. Nery and colleagues 29 ,30 studied 32 patients presented with atrioventricular conduction block; 11 of these patients were diagnosed with CS by the criteria set forth by the Japanese Ministry of Health and Welfare. Among these 11 patients, 2 ultimately developed VA during a mean follow-up of 21 months. Similarly, Kandolin and colleagues 31 studied 61 patients undergoing permanent pacemaker placement for atrioventricular conduction block; 18 of these patients were diagnosed with either CS or giant cell myocarditis by EMB. Among these 18 patients, 10 ultimately had VA during a mean follow-up of 48 months. Last, Te and colleagues 32 studied 2237 patients with systemic sarcoidosis followed for a mean of 11.4 years and showed an incidence of VT of 0.94% (or 85 per 100 000 patient-years).
Several studies indicate that patients with CS and left ventricular ejection fraction (LVEF) >35% may be at increased risk of VA despite their relatively preserved LV systolic function. 24, 33, 34 Therefore, risk-stratification techniques are needed to determine which patients with CS who do not have conventional indications for ICD placement nonetheless warrant placement of primary-prevention devices. Accumulating data support the use of advanced cardiac imaging and electrophysiology study for this purpose.
The presence of LGE on cardiac magnetic CMR, indicating myocardial fibrosis, predicts VA in patients with CS. [34] [35] [36] [37] Among the prospective analyses in the literature assessing the prognostic utility of CMR in patients with known or suspected CS, Smedema and colleagues 34 performed the study with the longest mean duration of follow-up of 56 months. These authors assessed 84 patients with pulmonary sarcoidosis undergoing CMR. The primary outcome was a composite of admission for congestive heart failure, sustained VT, appropriate ICD therapy, pacemaker implantation for high-degree atrioventricular conduction block, or cardiac death. The absence of LGE involving >8% of the left ventricular myocardium demonstrated a negative predictive value of 95%. Although VA was not reported as a stand-alone outcome, 1 patient experienced sudden death and 4 patients VA; all of these patients had LGE present on CMR. This analysis suggests that the quantity of LGE, in addition to the qualitative presence or absence, may have prognostic utility in CS. Negative predictive values in the remaining 4 prospective studies ranged from 94% to 99%, although it is important to note that each study defined unique composite outcomes, and no study defined VA as a stand-alone outcome. Taken together, these data suggest that CMR has a high negative predictive value for VA in patients with CS and may be a useful initial study in the risk-stratification process.
Because guidelines already support the use of prophylactic therapies to prevent VA in patients with poor LV systolic function, 5, 38 it is especially important to assess the prognostic utility of LGE and other risk-stratification techniques in patients with relatively preserved LV systolic function. Coleman and colleagues 33 recently performed a meta-analysis of 10 studies that assessed patients with known or suspected CS undergoing CMR. A total of 760 patients were included. The mean follow-up duration was 3 years. Approximately 20% of patients had known CS, and the remainder had suspected CS. The average LVEF was 58%. Among those patients with LVEF >50%, the presence of LGE predicted VA or death with an odds ratio 19.43 (7.62-49.56 ). In contrast, among patients with LVEF <50%, the presence of LGE did not predict VA or death (odds ratio, 2.16 [0.53-8.75]). This finding suggests that the utility of CMR in risk stratifying patients with CS is greatest among those with relatively preserved LV systolic function. It is important to note that the existing literature on LGE-CMR for risk stratification in CS may be subject to a number of limitations, including potential referral bias, lack of a uniform method of measuring LGE, and lack of uniform reporting of measures of interobserver variability. Multicenter prospective trials, including the ongoing CHASM-CS (Cardiac Sarcoidosis Multi-Center Prospective Cohort) (NCT01477359), are warranted.
The presence of abnormal FDG uptake on cardiac PET, indicating myocardial inflammation, predicts VT in patients with CS. 24 In the study noted earlier by Blankstein and colleagues, 24 the presence of focal FDG uptake on PET-especially in the RV-was strongly predictive of VT or death. The presence of both perfusion defects and FDG uptake predicted VT or death with a hazard ratio of 3.9 (1.5-10.3) at a medium follow-up of 1.5 years. The presence of FDG uptake in the RV predicted VT or death with a hazard ratio of 4.2 (1.8-9.5) at the same median follow-up. Although the negative predictive value of FDG uptake for VA was not reported, 13% of patients with normal PET studies (both normal perfusion and absence of FDG uptake) were noted to have VA on follow-up. This finding suggests that absence of acute inflammation does not exclude long-term risk of VA.
STATE OF THE ART
On the basis of these data, future guidelines may include cardiac PET along with CMR as a potential tool for risk stratification of patients with CS. Furthermore, because data from both CMR and PET studies suggest that RV involvement on LGE-CMR or FDG-PET may be strongly predictive of VA in patients with CS, 19, 24 there may be a role for future studies to explore the utility of primary-prevention ICD treatment in patients with CS and RV involvement, irrespective of RV or LV systolic function.
Analysis of scar heterogeneity as imaged by LGE is an emerging technique for prediction of sudden death in ischemic substrates. 39 Schmidt and colleagues 40 studied 47 patients with chronic myocardial infarction and LV systolic dysfunction. Using intermediate signal intensity on LGE imaging to identify areas of heterogeneous tissue (ie, admixed fibrosis and viable myocardium), they showed that the total mass of heterogeneous tissue predicts inducible VA on invasive or noninvasive programmed stimulation. A similar approach may be useful when applied to the complex substrate underlying CS. Last, programmed electric stimulation (PES) provides important prognostic information in patients with CS. Aizer and colleagues 41 studied 32 patients with CS undergoing PES. Among these patients, 12 had either spontaneous or inducible VA and underwent implantation of an ICD; of these patients, 9 (75%) had appropriate device therapy during follow-up. Twenty patients had neither spontaneous nor inducible VA; among these patients, 2 (10%) had VA or sudden death during follow-up. The positive predictive value of PES for prediction of VA or SCD in this study was 75%, whereas the negative predictive value was 90%.
Mehta and colleagues 42 subsequently studied 76 patients with suspected CS undergoing PES. Eight had inducible VA, among whom 3 (37%) had LVEF >40%, and 6 (75%) had VA during a median follow-up of 5 years. Sixty-eight patients had negative PES, among whom 1 (1.5%) had VA during the same median follow-up. The positive predictive value of PES for the prediction of VA in this study was 75%, whereas the negative predictive value was 98.5%. It is important to note that patients with a positive PES had a mean baseline LVEF of 36%, only 1 patient with a preserved LVEF had a positive PES, and this patient did not have VA on follow-up. Therefore, it is unclear whether PES had additive prognostic utility to LVEF in this study.
Last, in the study noted earlier by Smedema and colleagues, 34 19 patients underwent PES. The positive predictive value of PES for the prediction of VA was 75%; the negative predictive value was 91%. Although none of these studies stratified their analyses by LV systolic function or for abnormal CMR or PET, future studies could explore the additive prognostic utility of PES among patients with relatively preserved LV systolic function and abnormal CMR or PET. Table 2 summarizes the 2014 HRS Expert Consensus Recommendations for Risk Stratification for Sudden Cardiac Death in CS 6 and proposes updates to these recommendations based on data that have become available since its publication.
TREATMENT Corticosteroids
IS with corticosteroids is a mainstay of therapy for active sarcoidosis. However, corticosteroids have not been evaluated in a randomized fashion in CS, and their ef- fects on arrhythmic outcomes are unclear. Segawa and colleagues 43 followed 68 patients with CS who were treated with corticosteroids for a mean duration of 5.5 years. Among the 20 patients (29%) who had VA after initiation of corticosteroids, 14 (70%) had VA in the first 12 months of therapy. This finding suggests a correlation between corticosteroid use and VA; however, this finding may also be confounded by either the underlying inflammation that the corticosteroids are meant to target or the subsequent evolution of fibrosis after quiescence of inflammation.
Kato and colleagues 44 studied 20 patients with CS and atrioventricular conduction block; 7 of these patients were treated with corticosteroids. Among those 7 patients, 1 subsequently developed VT; among those 13 patients not treated, 8 subsequently developed VT. Although this study suggests a prophylactic role for corticosteroids in preventing VA in patients with CS, perhaps via mitigation of downstream fibrosis, it does not address the utility of corticosteroids in treating VA-which may be driven more by established fibrosis. Similarly, Yodogowa and colleagues 45 studied 31 patients with CS and frequent ventricular ectopy (>300 premature ventricular contractions per day). Patients were treated for 6 months with prednisone (an initial dose of 30 mg/day that was subsequently tapered to 10 mg/day). They observed a significant decrease in premature ventricular contraction frequency with corticosteroid treatment: 1820±2969 per day versus 742±1425 per day. Last, Yalagudri and colleagues 25 studied 18 patients presenting with unexplained VT who were ultimately diagnosed with CS. Patients with abnormal FDG uptake on PET were treated with corticosteroids (prednisolone 1 mg/kg/day ≤60 mg/ day). Those patients who had no recurrent VA within 8 weeks were tapered off of prednisolone, whereas methotrexate was introduced and titrated up. Prednisolone was discontinued by 12 weeks; methotrexate was titrated from an initial dose of 7.5 mg/week to a target dose of 20 mg/week and was continued for 2 years. Those patients who had recurrent VA within the first 8 weeks were treated with intensified IS. Among 14 patients with abnormal FDG uptake on PET who were treated with IS, 9 had no recurrence of VA; 5 had recurrent VA that responded to either intensified IS or radiofrequency ablation. This study suggests that the use of FDG-PET may be useful in identifying patients likely to benefit from corticosteroid therapy.
In light of these conflicting data, Sadek and coworkers 46 performed a meta-analysis on the use of corticosteroids in CS. They identified 10 studies, including 257 patients who were treated with corticosteroids and 42 who were not. Although the authors found that patients treated with corticosteroids had a higher rate of improvement in atrioventricular conduction as compared with those who were not, they note that there was insufficient evidence to draw conclusions about the effects of corticosteroids on other outcomes in CS. Because the effects of corticosteroids on arrhythmic outcomes remain unclear, 25, 43, 44, 46 future guidelines should deemphasize the need to trial IS before initiation of other therapies for prevention or treatment of VA in CS. When corticosteroids are used, serial FDG-PET exams may be useful for monitoring response to therapy. 47 
Antiarrhythmic Drugs
Antiarrhythmic drugs have not been studied in a randomized fashion for the treatment of VA in CS, and studies are conflicting with respect to their efficacy. Jefic and colleagues 48 prospectively studied 42 patients with CS. Of these patients, 21 developed or had initially presented with VA. Of these 21 patients, 2 (9.5%) were successfully managed with an ICD alone, 2 (9.5%) were successfully managed with an ICD and IS, and 8 (38%) were successfully managed with an ICD, IS, and antiarrhythmic drug therapy. Nine (43%) patients had VA refractory to medical therapy and ultimately required radiofrequency ablation. It is important to note that only 5 of these 9 patients were treated with amiodarone.
Catheter Ablation
The long-term success rate of catheter ablation (CA) among patients with CS and VA ranges from 25% to 56% if nonrecurrence of VA is the end point and 50% to 100% if a significant reduction of arrhythmic burden is the end point.
11,12,18,20,48-50 Among 6 studies assessing the role of CA in patients with CS and VA, 11, 12, 18, 20, 48, 49 Muser and colleagues 20 reported the largest cohort of 31 patients. The authors reported multiple clinical morphologies of VT in 15 patients (48%). All patients underwent CA; 8 (26%) underwent epicardial ablation and 18 (58%) underwent RV ablation. At a mean follow-up of 2.5 years, 16 patients (52%) had recurrent VA. If long-term success is defined as total freedom from VA, then 15 patients (48%) had long-term success in this study. However, if long-term success is defined as a significant reduction in the number of VA episodes, then 23 (90%) had long-term success in this study. Last, Papageorgiou and colleagues 50 performed a systematic review including 5 studies and 83 patients with CS undergoing CA. Among these patients, 54% suffered recurrent VA after CA, but only 21% failed to have a clinically significant reduction in arrhythmia burden after VA. The reasons for procedural failure may include septal intramural circuits, extensive RV scarring, site of origin close to the major epicardial coronary vessels, and site of origin in the para-Hisian region. 20 
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Treatment of VT Storm
Little is known about the optimal treatment of an electrical storm in patients with CS. In the study noted earlier by Segawa and colleagues, 43 among 68 patients with CS who were initiated on corticosteroid therapy, 10 (14.7%) subsequently had electrical storm, and 8 of these (80%) had an electrical storm within the first 12 months of therapy. These data raise concerns that corticosteroids may precipitate electric instability and could create reluctance to use corticosteroids in the treatment of an electrical storm. However, it is not possible to tease apart the effect of the corticosteroids from the effect of the underlying inflammation (or the evolution of fibrosis as the inflammation resolves) on electric outcomes. Stees and colleagues 51 reported a case of VT storm successfully treated with intravenous corticosteroids. The patient presented with >100 device tachytherapies in the preceding 7 days. Amiodarone did not appear to affect the frequency of VA. However, administration of 125 mg of intravenous solumedrol acutely terminated an episode of VA and subsequently reduced the frequency of VA. The patient then underwent CA, which was acutely successful. Similarly, in the study noted previously by Yalagudri and colleagues, 25 6 patients presented with incessant VT. Among these patients, 4 had evidence of inflammation on PET, whereas 2 did not. Those patients who had inflammation were successfully treated with oral prednisolone and methotrexate as detailed earlier; 2 of these patients had recurrent VA during follow-up; 1 of these recurrences was successfully treated with intravenous methylprednisolone and the other with intensification of oral therapy. Those patients without inflammation were successfully treated with antiarrhythmic drugs and CA. Among 4 patients without inflammation undergoing CA, there were no recurrent VA episodes at a follow-up ranging from 5 to 59 months. Last, in the study by Kumar et al 17 noted earlier, 7 patients presented with an electrical storm, and CA was successful in terminating the storm in 5 of these patients (71%); 2 of these patients had 2 separate presentations with an electrical storm, and CA was successful in terminating the storm in both. Hence, overall, the success rate of CA in terminating an electrical storm was 78%. The 2014 HRS Expert Consensus Recommendations for the Management of Ventricular Arrhythmias in CS suggest that an electrical storm be managed initially with a combination of antiarrhythmic drug therapy and IS if there is evidence of inflammation (or empirically if a PET scan cannot be obtained urgently). If these measures fail, then CA is recommended. Table 3 summarizes the 2014 HRS Expert Consensus Recommendations for the Management of Ventricular Arrhythmias in CS 6 and provides suggested updates to these recommendations on the basis of data that have become available since its publication.
Implantable Cardioverter-Defibrillators
There is a clear role for device therapy in patients with either a history of VA or poor LV systolic function. 6, 38 In patients with CS, if there is evidence of myocardial inflammation, the 2014 HRS Expert Consensus recommends a trial of IS before ICD implantation. 6 However, the effects of IS on LV systolic function may be modest. 47 Osborne et al 47 evaluated the effect of IS on FDG uptake and LV systolic function by cardiac PET in 23 patients with CS. Among these patients, 16 experienced an improvement in LVEF with an average increase of 8.6%, whereas 7 patients experienced a decline in LVEF. Therefore, in patients with an indication for ICD therapy and an LVEF <25% to 30%, it may be reasonable to pursue ICD implantation before immunosuppressive therapy. Furthermore, the utility of ICDs in patients with CS and relatively preserved LV systolic function (LVEF >35%) is not well established. Betensky and colleagues 52 studied 45 patients with CS and ICDs. Among those with a primary-prevention device, the mean LVEF was 48%. At a median duration followup of 2 years, 27% of patients had appropriate tachytherapies, whereas 17% had inappropriate therapies. Although the authors did not stratify their analysis by LV systolic function, they observed that patients with appropriate device therapies had a mean LVEF of 35%. Table 4 summarizes the 2014 HRS Expert Consensus At least 1 of the following: Because the majority of patients treated with corticosteroids do not experience a >10% increase in left ventricular ejection fraction, and some experience a decrement in left ventricular ejection fraction, 47 in patients with left ventricular ejection fraction <25% and active inflammation, clinicians may find implantable cardioverter-defibrillator implantation to be of benefit even before a trial of immunosuppressant therapy.
An indication for permanent pacemaker implantation
Because accumulating data show that right ventricular involvement on LGE-CMR or FDG-PET is strongly predictive of ventricular arrhythmia in patients with cardiac sarcoidosis, 24, 33 clinicians may find implantable cardioverter-defibrillator implantation to be of benefit in patients with cardiac sarcoidosis and extensive right ventricular involvement on either LGE-CMR or FDG-PET. Either of the following despite optimal medical therapy and, if active inflammation is present, a trial of immunosuppressive therapy:
Because inducible sustained ventricular arrhythmia is already listed as a IIa indication, and because electrophysiology study has a high negative predictive value in cardiac sarcoidosis, 42 we would remove left ventricular ejection fraction 36% to 49% as a stand-alone indication (ie, patients with left ventricular ejection fraction 36% to 49% who do not have inducible sustained ventricular arrhythmia should not be included in this recommendation). Recommendations for Implantation of ICDs in patients with CS 6 and provides suggested updates to these recommendations based on data that have become available since its publication. Table 5 summarizes the 2017 American Heart Association/American College of Cardiology/HRS Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death that pertain to patients with CS, 38 compares these guidelines with the 2014 HRS Expert Consensus recommendations, and proposes a reconciliation between the 2 documents in cases of apparent conflict.
CONCLUSIONS
Diagnosis of CS, especially in cases where there is limited or no extracardiac involvement, is challenging. There is a need for more sensitive and specific diagnostic criteria for CS. Future guidelines may consider permitting an imaging-based clinical pathway for the diagnosis of CS that would enable a clinical diagnosis of ICS. Clinical VA in patients with CS are difficult to predict. There is a need for improved risk-stratification strategies, especially in patients without conventional indications for ICD placement. Cardiac imaging with CMR and PET, as well as electrophysiology study, may be useful for this purpose. Future guidelines should highlight the high incidence of VA in patients with CS with significant RV involvement on cardiac imaging. Clinical VA in patients with CS are challenging to treat. The role of IS in treating electric instability remains unclear. Future guidelines could deemphasize the need to trial IS before initiation of other therapies for prevention or treatment of VA in CS.
II (Continued)
IIb: Implantable cardioverter-defibrillator implantation may be considered in patients with left ventricular ejection fraction in the range of 36% to 49% or a right ventricular ejection fraction <40% despite optimal medical therapy and immunosuppressant therapy (if there is active inflammation) IIb: In patients with cardiac sarcoidosis, left ventricular ejection fraction >35%, an expected meaningful survival of >1 y, and either late gadolinium enhancement on cardiac magnetic resonance imaging or 18-fluorodeoxyglucose uptake on positron emission tomography, clinicians may derive helpful information from electrophysiology study for the purpose of sudden cardiac death risk stratification and, if sustained ventricular arrhythmia is induced, clinicians may find an implantable cardioverterdefibrillator to be of benefit III Implantable cardioverter-defibrillator implantation is not recommended in patients with ≥1 of the following:
1. Incessant ventricular arrhythmias 2. New York Heart Association class IV symptoms 
